Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Oral Pirtobrutinib in Previously Treated CLL/SLL or NHL (Japan)
jRCT2031200245Phase 2Completed
- Sponsor
- Loxo Oncology
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL) and 5 more (11 arms), sponsored by Loxo Oncology. Primary endpoints: Maximum tolerated dose (MTD), Recommended dose for further study (recommended Phase 2 dose, RP2D) and 3 more. Started Dec 2020; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)Richter's syndrome (RS)
Beyond the preview
Go deeper on jRCT2031200245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200245.